Lucid Diagnostics Q1 2026: Stable Revenue, VA Deals, Medicare Approval Near

Lucid Diagnostics reports steady Q1 2026 performance, with 3,177 EsoGuard tests yielding $1.3M in revenue, slightly below target but within range. A successful public stock offering netted $16.8M, boosting cash to $45M pro forma. Medicare approval awaits, but VA contracts are progressing, with the first purchase order imminent. Strong conference performances and positive physician feedback bolster confidence. Sales team manages VA leads and steady volumes without increasing expenses. Quarter-end cash was $27.9M, with quarterly burn around $11-12M. Real-world data collection for publications and VA deals at solid rates. No international expansion plans yet, focusing on U.S. growth. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/47d0fc1d62c64a22